AzTrials
AzTrials

Osteoarthritis, KneeNCT03522025

GMK-UNI Anatomical UKA: Fixation of Cemented vs Cementless Designs

A study testing Unicompartmental Knee Arthroplasty (UKA) in people with Osteoarthritis, Knee, run by Medacta International SA at 5 sites in 2 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Unicompartmental knee arthroplasty (UKA) is the principal surgical alternative to the total knee arthroplasty (TKA) in patients with end-stage unicompartmental tibiofemoral osteoarthritis (OA) of the knee. Read more about this study

Who is it for?
Ages 18 to 95 years
Conditions the study is for
Osteoarthritis, Knee
What is being tested?
Unicompartmental Knee Arthroplasty (UKA)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
5 sitesin 2 countries
Study dates
15 Feb 2019to 1 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 95 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with end-stage unicompartmental tibiofemoral osteoarthritis (OA) of the knee that meet the indications for use according to Medacta implants included in this study (on-label use);
  • Those suffering from unilateral osteoarthritis or osteonecrosis of the medial compartment;
  • Frontal deformity < 10° (evaluated on weight-bearing long-axis x-rays);
  • Flexion contracture < 10°;
  • Intact ligaments;
  • Patients who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to the patient's surgery;
Show all 9Show fewer
  • Patient's age over 18 years old;
  • Patient with BMI < 40 kg/m2;
  • Patients must be willing to comply with the pre and post-operative evaluation schedule.

Who cannot join

  • Patients with one or more medical conditions identified as a contraindication defined by the labelling on any Medacta implants used in this study;
  • Any patient who cannot or will not provide informed consent for participation in the study;
  • Patients who need to undergo lateral unicompartmental knee arthroplasty;
  • Patients who need a revision surgery;
  • Patients who need a patella-femoral joint prosthesis;
  • Patients who had previously undergone high tibial osteotomy or ACL reconstruction;
Show all 10Show fewer
  • Patients with BMI ≥ 40 kg/m2;
  • Patients unable to understand and take action;
  • Any case not described in the inclusion criteria;
  • Patients aged under 18 years;

Trial locations and contacts

5 sites in 2 countries.

5 sites in 2 countries

France4 sites
  • Clinique Saint Vincent de Paul

    Bourgoin, France, 38300

  • Clinique du Mail

    La Rochelle, France, 17000

  • Centre Orthéo, Espace Fauriel

    Saint-Etienne, France, 42100

  • CHP Saint-Grégoire

    Saint-Grégoire, France, 35760

Other trials in France

Switzerland1 site
  • Dr. Näder Helmy

    Solothurn, Switzerland, 4500

Other trials in Switzerland

About this study

Official title: A Prospective, Multicenter, Randomised Study to Evaluate the Fixation of Cemented and Cementless Design of GMK-UNI Anatomical Knee Prosthesis.

Unicompartmental knee arthroplasty (UKA) is the principal surgical alternative to the total knee arthroplasty (TKA) in patients with end-stage unicompartmental tibiofemoral osteoarthritis (OA) of the knee. The current comparative randomized study aims to evaluate the fixation of cemented and cementless designs of GMK-UNI unicompartmental knee prosthesis over a 5-year time period.

Read the detailed description

The Primary objective is to compare the quality of fixation of cemented and cementless designs of GMK-UNI unicompartmental knee replacement at 2 years of follow-up.

The Secondary objectives include the evaluation of the patient improvement (subjective and objective) using the new Knee Society Score (KSS); the patient's anterior pain following UKA and any eventual patella-femoral disorder; Implant survival rate using the Kaplan Meier analysis; Post-op radiological findings and Adverse Events.

The Primary outcome aims to compare the occurrence of radiolucency's lines (both partial and complete) between the two study groups. Secondary outcomes include New KSS, OKS, Kaplan Meier analysis and stability and fixation of UNI prosthesis.

All patients who meet the inclusion criteria to take part in the current clinical study will be invited to participate before the surgery.

Subjects will be randomized during the screening; half of them will receive the cemented GMK-UNI anatomical UKA and the other half the cementless GMK-UNI anatomical UKA.

Clinical data will be recorded on CRF at those time-points:

  • Before the surgery
  • During the surgery
  • After the surgery at 3 months, 1, 2, 3 and 5 years.
Being tested
Unicompartmental Knee Arthroplasty (UKA)
Medical subject headings
Osteoarthritis, Knee

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Unicompartmental Knee Arthroplasty (UKA)Device

    Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.

Study groups in NCT03522025
Study groupRoleWhat they receive
GMK-UNI cemented fixation prosthesisActive comparatorUnicompartmental Knee Arthroplasty (UKA)
Receives: Device: Unicompartmental Knee Arthroplasty (UKA)
GMK-UNI cementless fixation prosthesisExperimentalUnicompartmental Knee Arthroplasty (UKA)
Receives: Device: Unicompartmental Knee Arthroplasty (UKA)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparing the occurrence of radiolucency's lines

    Compare occurrence of radiolucency's lines (both partial and complete)between the two study groups

    Measured: 5 yrs

Secondary outcomes (6)
  1. Anterior Knee Pian Scale (Kujala score)

    It's a 13-item knee specific self-report questionnaire. It documents response to 6 activities associated with anterior knee pain as well as symptoms such as limp, inability to weight bear through the affected limp, swelling...). It asks about duration of symptoms and limbs affected. Max score is 100 and lower scores indicate greater pain/disability. Scoring is hierarchical using various types of categorisation including "no difficulty-unable " and "no pain-severe pain". It is easy to understand and takes few minutes to complete.It has a good test-retest reliability.

    Measured: pre-op; 3months;1,2,3,5 yrs

  2. Implant survival rate using Kaplan Meier analysis

    Implant survival rate

    Measured: 5 yrs

  3. Recording of adverse events

    Any complication occurred during the study

    Measured: Throughout the study

  4. Oxford Knee Score

    The Oxford Knee Score (OKS) is a 12-item patient-reported PRO specifically designed and developed to assess function and pain after total knee replacement (TKR) surgery (arthroplasty).Each question is scored from 1 to 5, with 1 representing best outcome/least symptoms. Scores from each question are added so the overall score is from 12 to 60 (12 being the best outcome). The overall score for the OKS is acquired by simply summing the scores received for individual questions.

    Measured: Pre-op;3month;1,2,3,5yrs

  5. New Knee Society Score

    The new KSS System is a validated and responsive method for assessing objective and subjective outcomes after total and partial knee arthroplasty.It includes versions to be admninstered pre-op and post-op.It has an initial assessment of demographic deatils. The objective knee score includes VAS score of pain walking on level ground and on stairs or inclines, as well as ROM, an assessment of alignment, ligament stability along with deductions for flexion contracture or extensor lag. Pts then record their satisfaction, functional activities and expectations. It consists of 4 subscales: 1) objective knee score (7 items;100 points); 2) Satisfaction Score (5 items; 40 points);3) Expectation Score (3 items; 15 points); 4) Functional Activity Score (19 items; 100 points)

    Measured: Pre-op:3months;1,2,3,5 yrs

  6. Stability and fixation of unicompartmental prosthesis

    To evaluate the stability and fixation of the prosthesis

    Measured: 5 yrs

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2018
  2. Study start15 Feb 2019
  3. Primary completion1 Dec 2026 (estimated)
  4. Study completion1 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03522025
Sponsor's protocol ID
2017-01677
Other IDs
2017
Status last verified
Sep 2025
First submitted
27 Apr 2018
Last updated
25 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Unicompartmental Knee Arthroplasty (UKA) in people with Osteoarthritis, Knee, run by Medacta International SA at 5 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 25 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in France, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparing the occurrence of radiolucency's lines (time frame: 5 yrs). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in